Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma

Ann Hematol. 2023 Jan;102(1):243-244. doi: 10.1007/s00277-022-05037-w. Epub 2022 Nov 11.

Authors

Yosuke Masamoto¹, Arika Shimura¹, Akira Honda¹, Kazuki Taoka¹, Hiroaki Maki¹, Mineo Kurokawa^{2

3}

Affiliations

¹ Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
² Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. kurokawa@m.u-tokyo.ac.jp.
³ Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan. kurokawa@m.u-tokyo.ac.jp.

PMID: 36369496
DOI: 10.1007/s00277-022-05037-w

No abstract available

Publication types

Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bendamustine Hydrochloride / therapeutic use
Humans
Lymphoma, Follicular* / drug therapy
Lymphoma, Follicular* / pathology
Rituximab / therapeutic use

Substances

Bendamustine Hydrochloride
obinutuzumab
Antibodies, Monoclonal, Humanized
Rituximab